The safety of treatments for tobacco use disorder

References

• U.S. Department of Health and Human Services. The health consequences of smoking—50 years of progress: a report of the surgeon general. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
   Google Scholar
• Jamal A, Agaku IT, O’Connor E, et al. Current cigarette smoking among adults - United States, 2005–2013. MMWR. 2014 Nov 28;63(47):1108–1112.
   PubMed Web of Science ®Google Scholar
• Fiore MC. Treating tobacco use and dependence: 2008 update: clinical practice guideline. Rockville (MD): U.S. Department of Health and Human Services, Public Health Service, May; 2008.
   Google Scholar
• Community Guide Task Force on Community Preventive Services. Chapter 1, Tobacco. In: Kate W. Harris, Managing Editor, The guide to community preventive services: what works to promote health Part 1: changing risk behaviors and addressing environmental challenges. New York (NY): Oxford University Press; 2005.
   Google Scholar
• Malarcher A, Dube SR, Shaw L, et al. Quitting smoking among adults–United States, 2000–2010. MMWR. 2011;60(44):1513–1519.
   PubMedGoogle Scholar
• Sims TH, Fiore MC. Pharmacotherapy for treating tobacco dependence: what is the ideal duration of therapy? CNS Drugs. 2002;16(10):653–662.
   PubMed Web of Science ®Google Scholar
• Tobacco Use and Dependence Guideline Panel. Treating tobacco use and dependence: 2008 update. 2008 [cited 2013 Nov 22]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK63952/.
   Google Scholar
• Hays JT, Ebbert JO. Adverse effects and tolerability of medications for the treatment of tobacco use and dependence. Drugs. 2010 Dec 24;70(18):2357–2372.
   PubMed Web of Science ®Google Scholar
• Sabate E. Adherence to long-term therapies: evidence for action. Geneva (Switzerland): World Health Organization; 2003.
   Google Scholar
• Hays JT, Leischow SJ, Lawrence D, et al. Adherence to treatment for tobacco dependence: association with smoking abstinence and predictors of adherence. Nicotine Tob Res. 2010 Jun;12(6):574–581.
   PubMed Web of Science ®Google Scholar
• Foulds J, Hughes J, Hyland A, et al. Barriers to use of FDA-approved smoking cessation medications: implications for policy action. Soc Res Nicotine Tob. 2009 Mar.
   Google Scholar
• Hurt R, Lauger G, Offord K, et al. Nicotine-replacement therapy with use of a transdermal nicotine patch–a randomized double-blind placebo-controlled trial. Mayo Clin Proc. 1990;65(12):1529–1537.
   PubMed Web of Science ®Google Scholar
• Killen JD, Fortmann SP, Newman B, et al. Evaluation of a treatment approach combining nicotine gum with self-guided behavioral treatments for smoking relapse prevention. J Consult Clin Psychol. 1990 Feb;58(1):85–92.
   PubMed Web of Science ®Google Scholar
• Muller P, Abelin T, Ehrsam R, et al. The use of transdermal nicotine in smoking cessation. Lung. 1990;168(Suppl):445–453.
   PubMed Web of Science ®Google Scholar
• Rose JE, Levin ED, Behm FM, et al. Transdermal nicotine facilitates smoking cessation. Clin Pharmacol Ther. 1990 Mar;47(3):323–330.
   PubMed Web of Science ®Google Scholar
• Sutherland G, Stapleton JA, Russell MA, et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet. 1992 Aug 8;340(8815):324–329.
   PubMed Web of Science ®Google Scholar
• Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006 Jul 5;296(1):56–63.
   PubMed Web of Science ®Google Scholar
• Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006 Jul 5;296(1):47–55.
   PubMed Web of Science ®Google Scholar
• Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med. 2006 Aug 14–28;166(15):1561–1568.
   PubMed Web of Science ®Google Scholar
• Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med. 2006 Aug 14–28;166(15):1571–1577.
   PubMed Web of Science ®Google Scholar
• Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006 Jul 5;296(1):64–71.
   PubMed Web of Science ®Google Scholar
• Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999 Mar 4;340(9):685–691.
   PubMed Web of Science ®Google Scholar
• Hurt R, Sachs D, Glover E, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337(17):1195–1202.
   PubMed Web of Science ®Google Scholar
• Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146.
   PubMed Web of Science ®Google Scholar
• Ferguson SG, Shiffman S, Gwaltney CJ. Does reducing withdrawal severity mediate nicotine patch efficacy? A randomized clinical trial. J Consult Clin Psychol. 2006 Dec;74(6):1153–1161.
   PubMed Web of Science ®Google Scholar
• Tonnesen P, Lauri H, Perfekt R, et al. Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial. Eur Respir J. 2012 Sep;40(3):548–554.
   PubMed Web of Science ®Google Scholar
• Palmer KJ, Buckley MM, Faulds D. Transdermal nicotine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs. 1992 Sep;44(3):498–529.
   PubMed Web of Science ®Google Scholar
• Fiore MC, Jorenby DE, Baker TB, et al. Tobacco dependence and the nicotine patch. Clinical guidelines for effective use. JAMA. 1992;268(19):2687–2694.
   PubMed Web of Science ®Google Scholar
• Choi JH, Dresler CM, Norton MR, et al. Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res. 2003 Oct;5(5):635–644.
   PubMed Web of Science ®Google Scholar
• Nicotine replacement therapy for patients with coronary artery disease. Working Group for the Study of Transdermal Nicotine in Patients with Coronary artery disease. Arch Intern Med. 1994 May 9;154(9):989–995.
   PubMedGoogle Scholar
• Cahill K, Stevens S, Perera R, et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;5:CD009329.
   PubMed Web of Science ®Google Scholar
• Mills EJ, Thorlund K, Eapen S, et al. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation. 2014 Jan 7;129(1):28–41.
   PubMed Web of Science ®Google Scholar
• Roberts E, Evins AE, McNeill A, et al. Efficacy and acceptability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis. Addiction. 2015 Nov 23. DOI:10.1111/add.13236.
   PubMed Web of Science ®Google Scholar
• Hartman N, Leong GB, Glynn SM, et al. Transdermal nicotine and smoking behavior in psychiatric patients. Am J Psychiatry. 1991 Mar;148(3):374–375.
   PubMed Web of Science ®Google Scholar
• Dalack GW, Becks L, Hill E, et al. Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology. 1999 Aug;21(2):195–202.
   PubMed Web of Science ®Google Scholar
• Hughes JR, Lesmes GR, Hatsukami DK, et al. Are higher doses of nicotine replacement more effective for smoking cessation? Nicotine Tob Res. 1999 Jun;1(2):169–174.
   PubMedGoogle Scholar
• Hatsukami D, Mooney M, Murphy S, et al. Effects of high dose transdermal nicotine replacement in cigarette smokers. Pharmacol Biochem Behav. 2007 Jan;86(1):132–139.
   PubMed Web of Science ®Google Scholar
• Leischow SJ, Valente SN, Hill AL, et al. Effects of nicotine dose and administration method on withdrawal symptoms and side effects during short-term smoking abstinence. Exp Clin Psychopharmacol. 1997 Feb;5(1):54–64.
   PubMed Web of Science ®Google Scholar
• Dale LC, Hurt RD, Offord KP, et al. High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. JAMA. 1995 Nov 1;274(17):1353–1358.
   PubMed Web of Science ®Google Scholar
• Kalman D, Kahler CW, Tirch D, et al. Twelve-week outcomes from an investigation of high-dose nicotine patch therapy for heavy smokers with a past history of alcohol dependence. Psychol Addict Behav. 2004 Mar;18(1):78–82.
   PubMed Web of Science ®Google Scholar
• Fucito LM, Bars MP, Forray A, et al. Addressing the evidence for FDA nicotine replacement therapy label changes: a policy statement of the association for the treatment of tobacco use and dependence and the society for research on nicotine and tobacco. Nicotine Tob Res. 2014 Jul 1;16(7):909–914.
   PubMed Web of Science ®Google Scholar
• Stead LF, Lancaster T. Interventions to reduce harm from continued tobacco use. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005231. Review. PubMed PMID: 17636791.
   Google Scholar
• Batra A, Klingler K, Landfeldt B, et al. Smoking reduction treatment with 4-mg nicotine gum: a double-blind, randomized, placebo-controlled study. Clin Pharmacol Ther. 2005 Dec;78(6):689–696.
   PubMed Web of Science ®Google Scholar
• Bolliger CT, Zellweger JP, Danielsson T, et al. Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety. BMJ. 2000 Aug 5;321(7257):329–333.
   PubMed Web of Science ®Google Scholar
• Rennard SI, Glover ED, Leischow S, et al. Efficacy of the nicotine inhaler in smoking reduction: a double-blind, randomized trial. Nicotine Tob Res. 2006 Aug;8(4):555–564.
   PubMed Web of Science ®Google Scholar
• Wennike P, Danielsson T, Landfeldt B, et al. Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up. Addiction. 2003 Oct;98(10):1395–1402.
   PubMed Web of Science ®Google Scholar
• Kralikova E, Kozak JT, Rasmussen T, et al. Smoking cessation or reduction with nicotine replacement therapy: a placebo-controlled double blind trial with nicotine gum and inhaler. BMC Public Health. 2009;9:433.
   PubMed Web of Science ®Google Scholar
• Moore D, Aveyard P, Connock M, et al. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ. 2009;338:b1024.
   PubMed Web of Science ®Google Scholar
• Brokowski L, Chen J, Tanner S. High-dose transdermal nicotine replacement for tobacco cessation. Am J Health Syst Pharm. 2014 Apr 15;71(8):634–638.
   PubMedGoogle Scholar
• Fredrickson PA, Hurt RD, Lee GM, et al. High dose transdermal nicotine therapy for heavy smokers: safety, tolerability and measurement of nicotine and cotinine levels. Psychopharmacology. 1995 Dec;122(3):215–222.
   PubMed Web of Science ®Google Scholar
• Jorenby DE, Smith SS, Fiore MC, et al. Varying nicotine patch dose and type of smoking cessation counseling. JAMA. 1995 Nov 1;274(17):1347–1352.
   PubMed Web of Science ®Google Scholar
• Elrashidi MY, Ebbert JO. Emerging drugs for the treatment of tobacco dependence: 2014 update. Expert Opin Emerg Drugs. 2014 Jun;19(2):243–260.
   PubMed Web of Science ®Google Scholar
• McCarthy DE, Piasecki TM, Lawrence DL, et al. Psychological mediators of bupropion sustained-release treatment for smoking cessation. Addiction. 2008 Sep;103(9):1521–1533.
   PubMed Web of Science ®Google Scholar
• Kotlyar M, Drone D, Thuras P, et al. Effect of stress and bupropion on craving, withdrawal symptoms, and mood in smokers. Nicotine Tob Res. 2011 Jun;13(6):492–497.
   PubMed Web of Science ®Google Scholar
• Hughes JR, Stead LF, Hartmann-Boyce J, et al. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2014;1:CD000031.
   PubMed Web of Science ®Google Scholar
• Farley AC, Hajek P, Lycett D, et al. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev. 2012;1:CD006219.
   PubMedGoogle Scholar
• Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2013;2:CD007253.
   PubMedGoogle Scholar
• Burke MV, Ebbert JO, Hays JT. Treatment of tobacco dependence. Mayo Clin Proc. 2008 Apr;83(4):479–483. quiz 83-4.
   PubMed Web of Science ®Google Scholar
• Chun-Fai-Chan B, Koren G, Fayez I, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol. 2005 Mar;192(3):932–936.
   PubMed Web of Science ®Google Scholar
• Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry. 2006 Feb;163(2):232–239.
   PubMed Web of Science ®Google Scholar
• Dervaux A, Laqueille X. Antidepressant treatment and smoking cessation in bipolar disorder. JAMA. 2009 May 27;301(20):2093. DOI:10.1001/jama.2009.705. Author reply.
   PubMed Web of Science ®Google Scholar
• Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005 May 19;48(10):3474–3477.
   PubMed Web of Science ®Google Scholar
• Tsai ST, Cho HJ, Cheng HS, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther. 2007 Jun;29(6):1027–1039.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Oshima A, Fujimoto Y, et al. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther. 2007 Jun;29(6):1040–1056.
   PubMed Web of Science ®Google Scholar
• Williams JM, Anthenelli RM, Morris CD, et al. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2012 May;73(5):654–660.
   PubMed Web of Science ®Google Scholar
• Jimenez-Ruiz CA, Barrios M, Pena S, et al. Increasing the dose of varenicline in patients who do not respond to the standard dose. Mayo Clin Proc. 2013 Dec;88(12):1443–1445.
   PubMed Web of Science ®Google Scholar
• Evins AE, Cather C, Pratt SA, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA. 2014 Jan 8;311(2):145–154.
   PubMed Web of Science ®Google Scholar
• Williams KE, Reeves KR, Billing CB Jr, et al. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin. 2007 Apr;23(4):793–801.
   PubMed Web of Science ®Google Scholar
• Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2012;4:CD006103.
   PubMedGoogle Scholar
• Anthenelli RM, Morris C, Ramey TS, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. Ann Intern Med. 2013 Sep 17;159(6):390–400.
   PubMed Web of Science ®Google Scholar
• Chengappa KN, Perkins KA, Brar JS, et al. Varenicline for smoking cessation in bipolar disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014 Jul;75(7):765–772.
   PubMed Web of Science ®Google Scholar
• Kotz D, Viechtbauer W, Simpson C, et al. Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study. Lancet Respir Med. 2015;3(10):761–768.
   PubMed Web of Science ®Google Scholar
• Gibbons RD, Mann JJ. Varenicline, smoking cessation, and neuropsychiatric adverse events. Am J Psychiatry. 2013 Dec;170(12):1460–1467.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA updates label for stop smoking drug Chantix (varenicline) to include potential alcohol interaction, rare risk of seizures, and studies of side effects on mood, behavior, or thinking. 2015 [Internet]. [ cited 2015 Dec 22]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm436494.htm.
   Google Scholar
• Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2008;(1):CD000146. PubMed PMID: 15266423.
   Google Scholar
• Chang PH, Chiang CH, Ho WC, et al. Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: a systematic review and meta-analysis of randomized controlled trials. BMC Public Health. 2015;15:689. DOI:10.1186/s12889-015-2055-0.
   PubMed Web of Science ®Google Scholar
• Ramon JM, Morchon S, Baena A, et al. Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation. BMC Med. 2014;12:172.
   PubMed Web of Science ®Google Scholar
• Hajek P, Smith KM, Dhanji AR, et al. Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomised controlled trial. BMC Med. 2013;11:140. DOI:10.1186/1741-7015-11-140.
   PubMed Web of Science ®Google Scholar
• Koegelenberg CF, Noor F, Bateman ED, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. JAMA. 2014 Jul;312(2):155–161.
   PubMed Web of Science ®Google Scholar
• Ebbert JO, Hatsukami DK, Croghan IT, et al. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. JAMA. 2014 Jan 8;311(2):155–163.
   PubMed Web of Science ®Google Scholar
• Rose JE, Behm FM. Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm. Am J Psychiatry. 2014 Nov 1;171(11):1199–1205.
   PubMed Web of Science ®Google Scholar
• Hays JT, Ebbert JO. Bupropion sustained release for treatment of tobacco dependence. Mayo Clin Proc. 2003 Aug;78(8):1020–1024. quiz 4.
   PubMed Web of Science ®Google Scholar
• Evins AE. Reassessing the safety of varenicline. Am J Psychiatry. 2013 Dec;170(12):1385–1387.
   PubMed Web of Science ®Google Scholar